307543-71-1

基本信息
N-[(2-羥基-1-萘基)亞甲基]-2-噻吩磺酰胺
CS-2595
STF 083010
STF-083010
STF083010
STF 083010
N-[(2-Hydroxy-1-naphthalenyl)methylene]-2-thiophenesulfonamide
2-Thiophenesulfonamide, N-[(2-hydroxy-1-naphthalenyl)methylene]-
(E)-N-((2-hydroxynaphthalen-1-yl)methylene)thiophene-2-sulfonamide
物理化學(xué)性質(zhì)
制備方法

6339-87-3

708-06-5

307543-71-1
以2-噻吩磺酰胺(2.81g,13.5mmol)和2-羥基-1-萘甲醛(2.00g,12.3mmol)為原料,在25mL圓底燒瓶中混合,加入原硅酸四乙酯(2.81g,13.5mmol)。裝配小蒸餾頭并連接接收燒瓶。將反應(yīng)混合物加熱至150℃,維持6小時(shí),期間在接收燒瓶中收集生成的乙醇。反應(yīng)完成后,冷卻至室溫,過濾反應(yīng)燒瓶中析出的固體,并用100mL乙醚洗滌。通過重結(jié)晶(溶劑為乙酸乙酯與二氯甲烷的1:3混合溶液)純化,得到目標(biāo)產(chǎn)物N-((2-羥基萘-1-基)亞甲基)噻吩-2-磺酰胺(STF-083010),為綠色晶體(2.21g,收率57%)。產(chǎn)物結(jié)構(gòu)經(jīng)1H NMR、13C NMR和HRMS(ESI-TOF)確證。
參考文獻(xiàn):
[1] Patent: WO2014/176348, 2014, A1. Location in patent: Page/Page column 51; 52
報(bào)價(jià)日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價(jià)格 |
2025/05/22 | HY-15845 | STF-083010 | 307543-71-1 | 1 mg | 250元 |
2025/05/22 | HY-15845 | STF 083010 STF-083010 | 307543-71-1 | 5mg | 550元 |
2025/05/22 | HY-15845 | STF 083010 STF-083010 | 307543-71-1 | 10mM * 1mLin DMSO | 605元 |
常見問題列表
Ire1
STF-083010 shows cytostatic and cytotoxic activity in a dose- and time-dependent manner. Treatment with STF-083010 shows significant antimyeloma activity in model human multiple myeloma (MM) xenografts. RPMI 8226 human MM cells grown as tumor xenografts are treated in NSG mice. Intraperitoneal injection of STF-083010 alone (day 1, day 8) significantly inhibits the growth of these tumors. STF-083010 is an IRE1α-specific inhibitor. Four pancreatic cancer cell lines (Panc0403, Panc1005, BxPc3, MiaPaCa2) are treated with different combination of Bortezomib (10 or 50 nM) and STF (10 or 50 μM). The normalized isobologram analysis demonstrates synergistic activity between 10 μM STF and either 10 or 50 nM bortezomib in all four cell lines. Moreover, a higher concentration of STF (50 μM) attains synergy after addition of bortezomib either at a concentration of 10 nM when tested against BxPc3 cells, at a concentration of 50 nM against Panc1005 cells, and at either 10 or 50 nM against Panc0403 cells. STF-083010 (50 μM) suppresses the growth of p53-deficient human cancer cells.
Treatment with STF-083010 reduces the viability of HCT116 p53 -/- cells by approximately 20% compared with that of HCT116 p53 -/- cells. Administration of STF-083010 to tumors induced by HCT116 p53 -/- cells significantly reduces tumor volume and weight by 75% and 73% at the endpoint, respectively.